What is AstraZeneca Pharma India Ltd. Quarterly Revenue?

AstraZeneca Pharma India Ltd. Quarterly Revenue AstraZeneca Pharma Jun-2026 Quarterly Revenue is Rs 692 Cr which is growth of 28.7% YoY.

What is AstraZeneca Pharma India Ltd. Quarterly Net Profit?

AstraZeneca Pharma India Ltd. Quarterly Net Profit AstraZeneca Pharma Jun-2026 Quarterly Net Profit is Rs 38 Cr which is growth of -32.1% YoY.

What is AstraZeneca Pharma India Ltd. Annual Revenue?

AstraZeneca Pharma India Ltd. Annual Revenue AstraZeneca Pharma Mar-2026 Annual Revenue is Rs 2,304 Cr which is growth of 31.1% YoY.

What is AstraZeneca Pharma India Ltd. Annual Net Profit?

AstraZeneca Pharma India Ltd. Annual Net Profit AstraZeneca Pharma Mar-2026 Annual Net Profit is Rs 188 Cr which is growth of 62.0% YoY.

What is AstraZeneca Pharma India Ltd. Total Shareholders Fund?

AstraZeneca Pharma India Ltd. Total Shareholders Fund AstraZeneca Pharma Mar-2026 Total Shareholders Fund is Rs 873 Cr which is growth of 13.3% YoY.

What is AstraZeneca Pharma India Ltd. Total Assets?

AstraZeneca Pharma India Ltd. Total Assets AstraZeneca Pharma Mar-2026 Total Assets is Rs 1,989 Cr which is growth of 31.0% YoY.

What is AstraZeneca Pharma India Ltd. Book Value Per Share?

AstraZeneca Pharma India Ltd. Book Value Per Share AstraZeneca Pharma Mar-2026 Book Value Per Share is 349 Rs which is growth of 13.3% YoY.

What is AstraZeneca Pharma India Ltd. ROE?

AstraZeneca Pharma India Ltd. ROE AstraZeneca Pharma Mar-2026 ROE is 21% which is growth of 6.5% YoY.

What is AstraZeneca Pharma India Ltd. Cash From Operating Activity?

AstraZeneca Pharma India Ltd. Cash From Operating Activity AstraZeneca Pharma Mar-2026 Cash From Operating Activity is Rs -15 Cr which is growth of -123.2% YoY.

What is AstraZeneca Pharma India Ltd. Net Cash Flow?

AstraZeneca Pharma India Ltd. Net Cash Flow AstraZeneca Pharma Mar-2026 Net Cash Flow is Rs -88 Cr which is growth of -389.2% YoY.

AstraZeneca Pharma India Ltd.

NSE: ASTRAZEN | BSE: 506820

Expensive Performer

Download real time

US FDA Inspections

-5.50(-0.08%)

Near 52W Low of ₹6600.00

4,105

NSE+BSE Volume

NSE 23 Sep, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

AstraZeneca Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

AstraZeneca Pharma quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

Nested row level

Base Level

Export

POSITIVE
Quarterly Revenue AstraZeneca Pharma Jun-2026 Quarterly Revenue is Rs 692 Cr which is growth of 28.7% YoY.
NEGATIVE
Quarterly Net Profit AstraZeneca Pharma Jun-2026 Quarterly Net Profit is Rs 38 Cr which is growth of -32.1% YoY.

AstraZeneca Pharma India Ltd., Quarterly, standalone, All financials are in INR Cr and price data in INR
Indicator	Jun '26	Mar '26	Dec '25	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24	Mar '24	Dec '23	Sep '23	Jun '23
TOTAL_SR_Q Total Rev. ⌄	692	584.6	616.7	565.3	537.6	496.6	448.3	416.2	395.9	391.9	315.5	319.4	303.6
SR_Q Operating Rev.	682.8	578.6	611.6	559.1	526.3	480.5	440.3	408	387.5	383.2	305.8	311.1	295.5
OI_Q Other Income	9.2	6	5.1	6.2	11.2	16.2	8	8.2	8.4	8.7	9.7	8.4	8.1
OEXPNS_Q Operating Exp.	633.9	517.7	566.7	483.9	445.2	394.1	363.5	355.5	349.4	333.8	290.7	258.3	228.2
OEXPNS_Q Operating Exp.	633.9	517.7	566.7	483.9	445.2	394.1	363.5	355.5	349.4	333.8	290.7	258.3	228.2
OP_Q Operating Profit	48.9	60.9	44.8	75.2	81.1	86.4	77	52.5	38.1	49.4	15.1	52.8	67.3
OPMPCT_Q Operating Profit Margin %	7.17%	10.53%	7.33%	13.45%	15.41%	17.98%	17.49%	12.88%	9.83%	12.89%	4.92%	16.96%	22.76%
DEP_Q Depr.	5.2	5.6	3.8	2.6	16.6	17.7	9.1	9.3	3.9	3.8	3.7	3.7	3.8
INT_Q Interest	2	2	1.1	0.7	0.7	0.7	0.3	0.3	0.1	-0.1	0.6	0.5	0.2
PBT_Q Profit Before Tax	50.8	58.1	46.5	72.8	74.7	78.5	42	51	-15.2	54.4	20.4	73.4	71.4
TAX_Q Tax	12.8	13.3	14	18.6	18.9	20.2	11.2	12.6	-3.4	14.9	4.6	21	17.5
NP_Q Net Profit	37.9	44.9	32.6	54.2	55.8	58.3	30.9	38.4	-11.8	39.5	15.8	52.4	53.9
EPS_adj_Q EPS Adj. latest	15.2	18	13	21.7	22.3	23.3	12.3	15.4	-4.7	15.8	6.3	21	21.5
NP_TTM Net profit TTM	169.6	187.5	200.9	199.2	183.4	115.7	97	81.9	95.9	161.5	139.3	152.8	133
EPS_TTM Basic EPS TTM	67.9	75	80.4	79.7	73.3	46.3	38.8	32.8	38.3	64.6	55.7	61.1	53.2
results_pdf Results PDF
result_notes Result Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

AstraZeneca Pharma competitor comparison and performance snapshot within industry

AstraZeneca Pharma revenue mix: sales, profit, and capital employed breakups by segment

AstraZeneca Pharma annual results: revenue, profit, P&L, and margins as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Annual Revenue AstraZeneca Pharma Mar-2026 Annual Revenue is Rs 2,304 Cr which is growth of 31.1% YoY.
POSITIVE
Annual Net Profit AstraZeneca Pharma Mar-2026 Annual Net Profit is Rs 188 Cr which is growth of 62.0% YoY.

AstraZeneca Pharma India Ltd., Annual, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	TTM	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
SR_A Total Rev. Ann. ⌄	30.8%	22.8%	2,458.5	2,304.1	1,756.9	1,330.3	1,029.1	820.4	826.4	844.8	744.6	583.3	558.1	570.5
TotalOperatingRevenues_A Operating Rev. Ann.	31.4%	22.8%	2,432.1	2,275.6	1,716.3	1,295.5	1,003	805.6	813.6	831.8	728.3	571	543.7	563.7
OI_A Other Income Ann.	3%	17.4%	26.5	28.5	40.6	34.8	26.1	14.8	12.8	13	16.3	12.3	14.4	6.8
OEXPNS_A Operating Exp. Ann.	33.9%	24.3%	2,202.2	2,013.6	1,462.3	1,111.1	837.9	719.4	678.1	711.1	657	524.7	506.8	547.3
OEXPNS_A Operating Exp. Ann.	33.9%	24.3%	2,202.2	2,013.6	1,462.3	1,111.1	837.9	719.4	678.1	711.1	657	524.7	506.8	547.3
OP_A Operating Profit Ann.	16.6%	14.1%	229.9	262	254	184.5	165.1	86.2	135.5	120.7	71.3	46.3	36.9	16.4
OPMPCT_A OPM Ann. %	-10.9%	-7.1%		11.37%	14.46%	13.86%	16.05%	10.51%	16.39%	14.29%	9.58%	7.94%	6.62%	2.88%
TotalExpenses_A Total Exp. Ann. ⌄	33.8%	24%		2,046.6	1,503.8	1,127.2	854.7	737.3	699.3	730.8	671.9	539.5	522.6	564.7
OtherExpenses_A Other Exp. Ann.	19%	17.6%	266	368.6	241.9	275.1	218.8	177.3	163.6	189.2	228.5	190.1	170.8	178.9
EmployeeBenefitExpenses_A Employee Exp. Ann.	0.7%	3.8%	279.1	264.4	257.4	241.5	259.1	230.2	219.5	216.7	197.4	153.5	162	169.4
CostOfPowerPurchased_A Cost Of Power Purchased Ann.	-	-
CostOfFuel_A Cost Of Fuel Ann.	-	-
EBIDT_A EBITDA Ann.	15%	14.4%		290.5	294.6	219.3	191.2	100.9	148.3	133.7	87.6	58.5	51.3	23.2
EBIDTPCT_A EBITDA Ann. margin %	-12.1%	-6.8%		12.61%	16.77%	16.48%	18.58%	12.30%	17.95%	15.83%	11.76%	10.04%	9.20%	4.06%
INT_A Interest Ann.	95.7%	32.5%	5.7	4.5	1.5	1.2	0.6	1	1.1	1.1
DEP_A Depr.	20.6%	7.3%	17.2	28.6	40	14.9	16.3	17	20.1	18.6	14.9	14.7	15.8	17.4
PBT_A PBT Ann.	23.4%	14.7%	228.3	252.2	156.4	219.5	134.1	83	127.1	114	72.7	43.8	35.5	5.8
TAX_A Tax Ann.	23%	13.9%	58.6	64.7	40.6	58	34.8	21.4	33.8	41.8	18.2	17.9	15.5	0.5
PAT_A PAT Before ExtraOrdinary Items Ann. ⌄	23.6%	15%		187.5	115.7	161.5	99.3	61.6	93.3	72.2	54.5	25.9	20.1	5.3
IncomeMinorityInterest_A Minority Interest Income Ann.	-	-		-	-	-	-	-	-	-	-	-	-	-
NP_A Net Profit Ann.	23.6%	15%	169.6	187.5	115.7	161.5	99.3	61.6	93.3	72.2	54.5	25.9	20.1	5.3
NETPCT_A NPM Ann. %	-5.9%	-6.4%		8.24%	6.74%	12.46%	9.89%	7.64%	11.46%	8.68%	7.47%	4.53%	3.68%	0.93%
EPS_adj_A EPS Adj. latest Ann.	23.6%	15%		75	46.3	64.6	39.7	24.6	37.3	28.9	21.8	10.4	8	2.1
result_notes Result Notes				Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes	Notes
Annual_Reports Annual Reports

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Rev. Ann.

1Y CHG

31.1%

2Y CAGR

31.6%

3Y CAGR

30.8%

5Y CAGR

22.8%

7Y CAGR

17.5%

10Y CAGR

15%

Total Revenue Annual growth is higher than historical averages.

Net Profit Ann.

1Y CHG

62.1%

2Y CAGR

7.7%

3Y CAGR

23.6%

5Y CAGR

15%

7Y CAGR

19.3%

10Y CAGR

42.8%

Net Profit Annual growth is higher than historical averages.

Operating Exp. Ann.

1Y CHG

37.7%

2Y CAGR

34.6%

3Y CAGR

33.9%

5Y CAGR

24.3%

7Y CAGR

17.4%

10Y CAGR

13.9%

Operating Expenses Annual Cr growth is higher than historical averages.

AstraZeneca Pharma balance sheet as of Mar 2026: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Total Shareholders Fund AstraZeneca Pharma Mar-2026 Total Shareholders Fund is Rs 873 Cr which is growth of 13.3% YoY.
POSITIVE
Total Assets AstraZeneca Pharma Mar-2026 Total Assets is Rs 1,989 Cr which is growth of 31.0% YoY.

AstraZeneca Pharma India Ltd., Balance Sheet, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
TotalShareHoldersFunds_A Total ShareHolders Funds Ann. ⌄	14%	13.9%	872.8	770.4	711.9	588.7	511.4	456.2	364.4	300.8	246.9	222.9	156
EQCAP_A Equity Share Capital Ann.	0%	0%	5	5	5	5	5	5	5	5	5	5	5
TotalShareCapital_A Total Share Capital Ann.	0%	0%	5	5	5	5	5	5	5	5	5	5	5
ReservesAndSurplus_A Reserves Plus Surplus Ann.	14.1%	14%	867.8	765.4	706.9	583.7	506.4	451.2	359.4	295.8	241.9	217.9	151
TotalReservesAndSurplus_A Total Reserves Plus Surplus Ann.	14.1%	14%	867.8	765.4	706.9	583.7	506.4	451.2	359.4	295.8	241.9	217.9	151
LiabilityMinorityInterest_A Minority Interest Liability Ann.	-	-	-	-	-	-	-	-	-	-	-	-	-
TotalNonCurrentLiabilities_A Total Non Current Liabilities Ann. ⌄	122%	55.1%	134.5	44.8	9	12.3	12.5	15	14.7	2	6.7	2.3	1.3
DeferredTaxLiabilities_A Deferred Tax Liabilities Ann.	-	-
OtherLongTermLiabilities_A Other LongTerm Liabilities Ann.	217.7%	69%	118.7	38.5	2.8	3.7	5	8.6	9.3				1.3
CL_A Total Current Liabilities Ann. ⌄	36.8%	26.5%	981.8	703	357.1	383.9	332.7	303.5	327.2	259	207	190.3	248.4
TradePayables_A Trade Payables Ann.	50.9%	34.4%	782.7	456.3	196.5	227.9	188.1	178.4	209.7	168.2	95.3	87.7	94.6
OtherCurrentLiabilities_A Other Current Liabilities Ann.	7.8%	10.2%	143.2	140.2	117.2	114.4	104.4	88.2	73.2	56.2	76.6	75.2	120.7
ShortTermProvisions_A ST Provisions Ann.	10.3%	8.7%	55.9	106.5	43.4	41.7	40.2	36.9	44.4	34.6	35	27.5	33.1
TL_A Total Capital Plus Liabilities Ann.	26.4%	20.8%	1,989.1	1,518.1	1,078	984.9	856.6	774.7	706.4	561.8	460.5	415.5	405.7
FixedAssets_A Fixed Assets Ann. ⌄	18.7%	6.7%	117.5	64.2	67	70.2	76.7	85	95.8	81.7	79	91.7	103.7
TangibleAssets_A Tangible Assets Ann.	19.5%	7.7%	117.5	63.6	64.6	68.9	74.5	81	71.5	74.8	75.5	86.8	97.4
IntangibleAssets_A Intangible Assets Ann.	-	-		0.7	2.1
CapitalWorkInProgress_A Capital Work In Progress Ann.	-	-			0.3	1.3	2.2	4	24.2	6.9	3.6	4.8	6.3
TotalNonCurrentAssets_A Total Non Current Assets Ann. ⌄	18.6%	9.8%	249.2	175.8	145.3	149.4	150.9	156	164	157.1	139.6	163.9	137.4
NonCurrentInvestments_A Non Current Investments Ann.	-	-
DeferredTaxAssets_A Deferred Tax Assets Ann.	22.2%	21.1%	37.8	41.6	21.3	20.7	16.3	14.5	14.6	23.4	32.6	40.2
LongTermLoansAndAdvances_A LT Loans Plus Advances Ann.	-37%	-51.9%		0.1	0.3	0.9	0.4	4.3	3.9	2.9	2.6	2.9	33.2
OtherNonCurrentAssets_A Other Non Current Assets Ann.	17.6%	12.5%	93.9	69.9	56.9	57.7	57.5	52.1	49.7	49.1	25.4	29.2	0.6
CA_A Total Current Assets Ann. ⌄	27.7%	23%	1,739.9	1,342.4	932.7	835.5	705.7	618.8	542.3	404.7	320.9	251.6	268.3
CurrentInvestments_A Current Investments Ann.	-	-
TradeReceivables_A Trade Receivables Ann.	25.7%	20.2%	213.7	184.9	153.1	107.5	85.9	85.2	83.2	79.8	54.6	43	84.4
CashAndCashEquivalents_A Cash Plus Cash Equivalents Ann.	-3.6%	4.9%	447.7	536.7	505.8	500.5	448.5	352.4	252.5	173.3	125.9	115.6	76.8
ShortTermLoansAndAdvances_A ST Loans Plus Advances Ann.	108%	17.6%	0.9	0.3	0.1	0.1	0.1	0.4	0.8	0.8	1.2	1.2	27.6
OtherCurrentAssets_A Other Current Assets Ann.	10.6%	19%	50.3	72	45.7	37.2	31	21.1	40.6	32.8	26	34	2.7
TA_A Total Assets Ann.	26.4%	20.8%	1,989.1	1,518.1	1,078	984.9	856.6	774.7	706.4	561.8	460.5	415.5	405.7
ContingentLiabilities_A Contingent Liabilities plus Commitments Ann.	-2.7%	6.4%	121.7	98.5	138.3	132.3	124.6	89.2	69.2	32.6	11.9	17.3	42.8
BonusEquityShareCapital_A Bonus Equity Share Capital Ann.	0%	0%	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
NonCurrentInvestmentsUnquotedBookValue_A Non Current Investments Unquoted Book Value Ann.	-	-
CurrentInvestmentsUnquotedBookValue_A Current Investments Unquoted Book Value Ann.	-	-

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Total Assets Ann.

1Y CHG

31%

2Y CAGR

35.8%

3Y CAGR

26.4%

5Y CAGR

20.8%

7Y CAGR

19.8%

10Y CAGR

17.2%

Total Assets Annual growth is higher than historical averages.

Total Current Liabilities Ann.

1Y CHG

39.7%

2Y CAGR

65.8%

3Y CAGR

36.8%

5Y CAGR

26.5%

7Y CAGR

21%

10Y CAGR

14.7%

Total Current Liabilities Annual Cr growth is higher than historical averages.

Total ShareHolders Funds Ann.

1Y CHG

13.3%

2Y CAGR

10.7%

3Y CAGR

14%

5Y CAGR

13.9%

7Y CAGR

16.4%

10Y CAGR

18.8%

Total ShareHolders Funds Annual growth is lower than historical averages.

AstraZeneca Pharma ROE, ROCE, book value, and debt-to-equity ratio as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

POSITIVE
Book Value Per Share AstraZeneca Pharma Mar-2026 Book Value Per Share is 349 Rs which is growth of 13.3% YoY.
POSITIVE
ROE AstraZeneca Pharma Mar-2026 ROE is 21% which is growth of 6.5% YoY.

AstraZeneca Pharma India Ltd., Ratios, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
BVSH_A BVSH Ann.	14%	13.9%	349.1	308.1	284.8	235.5	204.6	182.5	145.8	120.3	98.8	89.2	62.4
ROA_A RoA Ann. %	-2.2%	-4.8%	9.42%	7.62%	14.98%	10.08%	7.19%	12.04%	10.22%	9.69%	5.62%	4.82%	1.29%
ROE_A ROE Ann. %	8.4%	1%	21.48%	15.02%	22.68%	16.86%	12.04%	20.45%	19.81%	18.10%	10.49%	8.99%	3.37%
ROCE_A ROCE Ann. %	-3.7%	-0.9%	26.00%	31.23%	28.34%	29.11%	16.03%	27.20%	30.36%	23.99%	17.27%	15.76%	3.66%
ProfitabilityHeader Profitability Ratio ⌄
PBDITMargin_A EBITDA Ann. Margin %	-12.5%	-6.9%	12.76%	17.16%	16.92%	19.06%	12.52%	18.22%	16.07%	12.02%	10.25%	9.44%	4.11%
PBITMargin_A EBIT Ann. Margin %	-12.9%	-6.1%	11.51%	14.83%	15.77%	17.44%	10.42%	15.75%	13.83%	9.97%	7.67%	6.52%	1.02%
PBTMargin_A PBT Ann. Margin %	-6.1%	-6.6%	11.08%	9.11%	16.94%	13.37%	10.30%	15.62%	13.70%	9.97%	7.67%	6.52%	1.02%
NETPCT_A NPM Ann. %	-5.9%	-6.4%	8.24%	6.74%	12.46%	9.89%	7.64%	11.46%	8.68%	7.47%	4.53%	3.68%	0.93%
ASETTO_A Asset Turnover Ann. %	5.7%	3.4%	1.3	1.3	1.3	1.1	1	1.1	1.3	1.4	1.3	1.3	1.4
LiquidityHeader Liquidity Ratio ⌄
CRATIO_A Current Ratio Ann.	-6.5%	-2.1%	1.8	1.9	2.6	2.2	2.1	2	1.7	1.6	1.6	1.3	1.1
QuickRatio_A Quick Ratio Ann.	-25.6%	-14.1%	0.7	1.1	2	1.7	1.7	1.5	1.2	1.1	1	1	0.8
DividendPayoutNP_A Dividend Payout to NP Ann.	26%	32%	0.4	0.5	0.3	0.2	0.1	0.1	0
EarningRetention_A Earning Retention Ann. %	-10.5%	-9.5%	57.34%	48.16%	75.24%	79.86%	91.89%	94.65%	96.54%
CashEarningRetention_A Cash Earning Retention Ann. %	-8.7%	-8%	62.99%	61.48%	77.34%	82.70%	93.64%	95.60%	97.25%
CashEarningRetention_A Cash Earning Retention Ann. %	-8.7%	-8%	62.99%	61.48%	77.34%	82.70%	93.64%	95.60%	97.25%
ValuationHeader Valuation Ratio ⌄
EnterpriseValue_A EnterpriseValue Ann.	35.5%	21.4%	18,950.9	20,979.2	12,795.2	7,617.8	5,940.2	7,173.2	5,726.4	4,822.5	2,190.3	2,236.2	2,814.8
EVPerNetSales_A EV Per Net Sales Ann.	3%	-1.2%	8.3	12.2	9.9	7.6	7.4	8.8	6.9	6.6	3.8	4.1	5
PBV_A Price To Book Value Adjusted	-12.3%	-12.2%	19.21	24.68	23.55	28.48	32.78	36.75	46	55.73	67.89	75.22	107.46
EVPerEBITDA_A EV Per EBITDA Ann.	17.9%	6.1%	65.2	71.2	58.4	39.8	58.9	48.4	42.8	55.1	37.4	43.6	121.4
MarketCapPerSales_A Market Cap Per Sales Ann.	1.6%	-1.8%	8.5	12.5	10.3	8.1	7.9	9.3	7.2	6.9	4.1	4.3	5.1
RetentionRatios_A Retention Ratio Ann. %	-10.5%	-9.5%	57.33%	48.15%	75.23%	79.85%	91.88%	94.64%	96.53%
EYield_A Earnings Yield Ann.	-	-	0	0	0	0	0	0	0	0	0	0
DEBT_CE_A Total Debt to Total Equity Ann.

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

ROE Ann. %

1Y CHG

43%

2Y CAGR

-2.7%

3Y CAGR

8.4%

5Y CAGR

7Y CAGR

2.5%

10Y CAGR

20.3%

ROE Annual % is growing faster than historical averages.

RoA Ann. %

1Y CHG

23.6%

2Y CAGR

-20.7%

3Y CAGR

-2.2%

5Y CAGR

-4.8%

7Y CAGR

-0.4%

10Y CAGR

22%

RoA Annual % is growing faster than historical averages.

Current Ratio Ann.

1Y CHG

-5.3%

2Y CAGR

-16.8%

3Y CAGR

-6.5%

5Y CAGR

-2.1%

7Y CAGR

1.7%

10Y CAGR

Current Ratio Annual is falling faster than historical averages.

AstraZeneca Pharma cash flow: net, operating, investing, and financing flows as of Mar 2026 – 11 year history

Nested row level

Base Level

Reporting Type

Standalone

Cell Data

Actual

Table Settings

YoY & New to Old

CAGR Columns

Select...

Nested row level

Base Level

Export

NEGATIVE
Cash From Operating Activity AstraZeneca Pharma Mar-2026 Cash From Operating Activity is Rs -15 Cr which is growth of -123.2% YoY.
NEGATIVE
Net Cash Flow AstraZeneca Pharma Mar-2026 Net Cash Flow is Rs -88 Cr which is growth of -389.2% YoY.

AstraZeneca Pharma India Ltd., Cash Flow, standalone, All financials are in INR Cr and price data in INR
Indicator	CAGR 3 Yrs	CAGR 5 Yrs	Mar '26	Mar '25	Mar '24	Mar '23	Mar '22	Mar '21	Mar '20	Mar '19	Mar '18	Mar '17	Mar '16
CFO_A Cash from Operating Act. Ann. ⌄	-	-	-15.1	65.4	27.9	58.3	100.8	104.8	87.4	55	8.8	38.1	57
PBT_A PBT Ann.	23.4%	14.7%	252.2	156.4	219.5	134.1	83	127.1	114	72.7	43.8	35.5	5.8
INT_A Interest Ann.	95.7%	32.5%	4.5	1.5	1.2	0.6	1	1.1	1.1
TAX_A Tax Ann.	23%	13.9%	64.7	40.6	58	34.8	21.4	33.8	41.8	18.2	17.9	15.5	0.5
CFI_A Cash from Investing Act. Ann.	1.1%	-35.9%	18.7	30.8	21.7	18.1	4.7	173	-170.8	4.3	-9.4	0.3	-3.6
CFA_A Cash from Financing Act. Ann.	-	-	-92	-65.6	-44.4	-24.5	-9.5	-9	-6.4				-0.5
NCF_A Net Cash Flow Ann. ⌄	-	-	-88.4	30.6	5.2	51.9	96.1	268.8	-89.7	59.3	-0.6	38.4	52.9
CashAndCashEquivalentBeginOfYear_A Cash Plus Cash Eqv. Begin Of Year Ann.	6.1%	45%	536.1	505.6	500.3	448.4	352.3	83.5	173.2	114	114.6	76.2	23.3
CashAndCashEquivalentEndOfYear_A Cash Plus Cash Eqv. End Of Year Ann.	-3.6%	4.9%	447.7	536.1	505.6	500.3	448.4	352.3	83.5	173.2	114	114.6	76.2

*All financials are in INR Cr and price data in INR

Add metric to table

Search...

Cash from Investing Act. Ann.

1Y CHG

-39.3%

2Y CAGR

-7.2%

3Y CAGR

1.1%

5Y CAGR

-35.9%

7Y CAGR

23.4%

Cash from Investing Activity Annual is falling faster than historical averages.

AstraZeneca Pharma investor presentations, annual reports, credit ratings, and earnings calls with AI summary, video, and audio access

Quarterly
Competitors/Peers
Revenue Mix
Annual
Balance Sheet
Ratios
Cash Flow
Documents

Near 52W Low of ₹6600.00

AstraZeneca Pharma quarterly and annual financials: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents